H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11
Galectin Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Optimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost Prospects
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position
Galectin Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)
Galectin Therapeutics Analyst Ratings
Buy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stability
Galectin Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Arce's Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial Outlook
Galectin Therapeutics Analyst Ratings
H.C. Wainwright Remains a Buy on Galectin Therapeutics (GALT)
Analysts' Top Healthcare Picks: Galectin Therapeutics (GALT), Cabaletta Bio (CABA)
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
H.C. Wainwright Sticks to Their Buy Rating for Galectin Therapeutics (GALT)
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
H.C. Wainwright Sticks to Its Buy Rating for Galectin Therapeutics (GALT)